Literature DB >> 23970381

Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia.

Hanumantha R Pokala1, David Leonard, Jennifer Cox, Pat Metcalf, John McClay, Jane Siegel, Naomi Winick.   

Abstract

BACKGROUND: Healthcare associated mold infections (HAEMI) increase morbidity and mortality in children with leukemia. Excavation adjacent to Children's Medical Center Dallas (CMCD) April 2006-February 2007 provided an opportunity to determine if excavation adjacent to a hospital building is associated with increased risk of developing HAEMI in children receiving intensive chemotherapy for acute leukemia.
METHODS: Children who began receiving intensive chemotherapy for acute leukemia at CMCD from 2004 to 2008 were identified (n = 275). Exposures to the CMCD campus during intensive chemotherapy and duration of neutropenia per exposure were recorded. Proven, probable, or possible invasive fungal disease (IFD) was classified using EORTC/MSG guidelines. Institutional guidelines categorized mold infections as definite or possible HAEMI. A bivariate time-to-event model compared the association of excavation with HAEMI and yeast infections, controlling for neutropenia.
RESULTS: There were 7,454 CMCD exposures, 1,007 (13.5%) during excavation. Of 50 cases of IFD, 31 were HAEMI. By time-to-event analysis exposure to the CMCD campus during the excavation period was significantly associated with HAEMI (HR = 2.8, P = 0.01) but not yeast infections (HR = 0.75, P = 0.75). Neutropenia was significantly associated with both HAEMI and yeast infections (P < 0.001). Voriconazole prophylaxis did not prevent HAEMI in 42% of the 14 patients with AML who had been receiving this agent.
CONCLUSION: This study is the first to demonstrate an association between exposure to hospital construction that includes excavation and HAEMI in pediatric oncology patients. Since neutropenic patients need protection from aerosolized fungal spores during visits to expanding medical centers, preventive strategies with adherence monitoring need additional study.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute leukemia; hospital construction; mold infections; pediatric oncology

Mesh:

Substances:

Year:  2013        PMID: 23970381      PMCID: PMC4048739          DOI: 10.1002/pbc.24685

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  34 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

Review 2.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

3.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

4.  Effectiveness of preventive measures for hemato-oncologic patients undergoing stem cell transplantation during a period of hospital construction.

Authors:  Jutta Berger; Birgit Willinger; Magda Diab-Elschahawi; Alexander Blacky; Peter Kalhs; Walter Koller; Ojan Assadian; Karl J Aichberger
Journal:  Am J Infect Control       Date:  2011-06-25       Impact factor: 2.918

5.  Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes.

Authors:  P A Pizzo; K J Robichaud; R Wesley; J R Commers
Journal:  Medicine (Baltimore)       Date:  1982-05       Impact factor: 1.889

6.  Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study.

Authors:  T J Walsh; M Rubin; J Hathorn; J Gress; M Thaler; J Skelton; J McKnight; M Browne; D Marshall; D Cotton
Journal:  Arch Intern Med       Date:  1991-04

Review 7.  Glucocorticoids and invasive fungal infections.

Authors:  Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Lancet       Date:  2003-11-29       Impact factor: 79.321

8.  Aspergillus fumigatus and other thermotolerant fungi generated by hospital building demolition.

Authors:  A J Streifel; J L Lauer; D Vesley; B Juni; F S Rhame
Journal:  Appl Environ Microbiol       Date:  1983-08       Impact factor: 4.792

9.  Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction.

Authors:  F A Sarubbi; H B Kopf; M B Wilson; M R McGinnis; W A Rutala
Journal:  Am Rev Respir Dis       Date:  1982-01

10.  Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group.

Authors: 
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

View more
  6 in total

Review 1.  Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.

Authors:  Kaitlin Benedict; Malcolm Richardson; Snigdha Vallabhaneni; Brendan R Jackson; Tom Chiller
Journal:  Lancet Infect Dis       Date:  2017-07-31       Impact factor: 25.071

2.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

3.  Mold contamination in a controlled hospital environment: a 3-year surveillance in southern Italy.

Authors:  Giuseppina Caggiano; Christian Napoli; Caterina Coretti; Grazia Lovero; Giancarlo Scarafile; Osvalda De Giglio; Maria Teresa Montagna
Journal:  BMC Infect Dis       Date:  2014-11-15       Impact factor: 3.090

4.  Community Airborne Mold Spore Counts and Invasive Fungal Disease Risk Among Pediatric Hematological Malignancy and Stem Cell Transplant Patients.

Authors:  Mohammed A Almatrafi; Victor M Aquino; Tamra Slone; Rong Huang; Michael Sebert
Journal:  Open Forum Infect Dis       Date:  2021-09-25       Impact factor: 3.835

5.  Infection Prevention in Transplantation.

Authors:  Steven A Pergam
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

6. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.